Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trialsopen access
- Authors
- Hoang, Tung; Myung, Seung-Kwon; Pham, Thu Thi; Park, Boyoung
- Issue Date
- Mar-2020
- Publisher
- MDPI
- Keywords
- ALK inhibitors; non-small cell lung cancer; crizotinib; ceritinib; alectinib
- Citation
- CANCERS, v.12, no.3, pp.1 - 14
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCERS
- Volume
- 12
- Number
- 3
- Start Page
- 1
- End Page
- 14
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146078
- DOI
- 10.3390/cancers12030526
- ISSN
- 2072-6694
- Abstract
- This study aimed to evaluate the efficacy of anaplastic lymphoma kinase (ALK)-inhibitors in the treatment of ALK-positive non-small cell lung cancer (NSCLC) by using a meta-analysis of clinical trials. We searched PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov by using keywords related to the topic in August 2018. The pooled effect sizes were calculated based on a random-effects model. We also performed subgroup meta-analysis by types of ALK inhibitors (crizotinib, ceritinib, and alectinib). A total of 20 clinical trials with 10 single-arm trials and 10 double-arm trials were included in the final meta-analysis. The median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), 1 year survival rate, and 2 year survival rate were 19.14 months, 8.47 months, 62%, 78%, 74%, and 62%, respectively. ALK inhibitors showed a significantly superior efficacy compared with chemotherapy (hazard ratio (HR) for OS, 0.83; HR for PFS, 0.43; rate difference (RD) for ORR, 0.23; and RD for DCR, 0.10). The current meta-analysis of clinical trials showed the significant efficacy of ALK inhibitors in the treatment of ALK-positive NSCLC. Further head-to-head trials are needed to compare their efficacy with other types of NSCLC treatment regimens. PROSPERO registration: CRD42018085987.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 예방의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146078)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.